Table 1.
List of antiepileptic compounds used in this study and associated abbreviations, therapeutic plasma levels for epilepsy treatment, toxicity levels, and experimental dosing concentrations
| Drug name | Drug abbreviation | Therapeutic μg/ml | Toxic | Dosing concentrations μg/ml |
|---|---|---|---|---|
| Temozolomide | TMZ | 4–11 | Determined by myelosupression/hepatotoxicity | 0.04, 0.4, 4, 10, 20, 40 |
| Dexamethasone | DEX | 2.6–18 | Rat LD50 3 gm/kg | 0.008, 0.08, 0.8, 16, 40 |
| Valproic acid | VPA | 50–150 | 450–850 μg/ml | 10, 100, 250, 500, 1000 |
| Carbamazepine | CBZ | 4–12 | 18–42.8 μg/ml | 1, 2, 4, 8, 16 |
| Ethosuximide | ESX | 40–160 | >150 μg/ml | 10, 20, 40, 80, 160 |
| Gabapentin | GBP | 2–8.6 | 40–100 g | 0.2, 2, 10, 20 |
| Lamotrigine | LTG | 0.5–5.4 | 13–62.4 μg/ml | 0.2, 2, 10, 20 |
| Levetiracetam | LEV | 6.85–72 | 60–400 μg/ml | 5, 10, 20, 40, 80 |
| Magnesium sulfate | MgSO4 | 240.83–421.45 | Plasma Mg level of 4–12 mEq/L | 5.55, 16.6, 50, 150, 450 |
| Oxcarbazepine | OXC | 3–35 | 30–40 μg/ml | 2.5, 5, 10, 20, 40 |
| Licarbazepine (R-(−)-10-hydroxy-10,11-dihydro-carbamazepine/monohydroxycarbamazepine) | R-(−)-MHC | 3–35 | 30–40 μg/ml | 12.5, 25, 75 |
| Eslicarbazepine (S-(+)-10-hydroxy- 10,11-dihydro- carbamazepine/monohydroxycarbamazepine) | S-(+)-MHC | 3–35 | 30–40 μg/ml | 12.5, 25, 75 |
| Phenytoin | PHT | 10–20 | 20–40 μg/ml | 0.04, 0.4, 4, 20, 40 |
| Primidone | PRM | 5–12 | 40–80 μg/ml | 0.2, 1, 5, 12.5, 25 |
| Tiagabine | TGB | 0.04–0.55 | 0.7–4.6 μg/ml | 0.0008, 0.008, 0.08, 0.8 |
| Topiramate | TPM | 2–19 | 9.4–170 μg/ml | 0.2, 2, 10, 20 |
| Vigabatrin | VBT | 5.3 | 60 g | 0.04, 0.4, 4, 20, 40 |